blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2968297

EP2968297 - MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  02.08.2019
Database last updated on 21.05.2024
FormerThe patent has been granted
Status updated on  24.08.2018
FormerGrant of patent is intended
Status updated on  18.04.2018
FormerExamination is in progress
Status updated on  20.10.2017
Most recent event   Tooltip01.07.2022Lapse of the patent in a contracting state
New state(s): MK		published on 03.08.2022  [2022/31]
Applicant(s)For all designated states
Verseon Corporation
47071 Bayside Parkway
Fremont, California 94538 / US
[2019/07]
Former [2016/03]For all designated states
Verseon Corporation
48820 Kato Road, Suite 100B
Fremont, California 94538 / US
Inventor(s)01 / SHORT, Kevin, Michael
48820 Kato Road
Suite 100b
Fremont, CA 94538 / US
02 / PHAM, Son, Minh
48820 Kato Road
Suite 100b
Fremont, CA 94538 / US
03 / WILLIAMS, David, Charles
48820 Kato Road
Suite 100b
Fremont, CA 94538 / US
04 / KITA, David, Ben
48820 Kato Road
Suite 100b
Fremont, CA 94538 / US
 [2016/03]
Representative(s)HGF
1 City Walk
Leeds LS11 9DX / GB
[N/P]
Former [2018/39]HGF Limited
1 City Walk
Leeds LS11 9DX / GB
Former [2016/03]HGF Limited
Belgrave Hall
Belgrave Street
Leeds LS2 8DD / GB
Application number, filing date14764515.417.03.2014
[2016/03]
WO2014US30853
Priority number, dateUS201361789358P15.03.2013         Original published format: US 201361789358 P
[2016/03]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2014145986
Date:18.09.2014
Language:EN
[2014/38]
Type: A1 Application with search report 
No.:EP2968297
Date:20.01.2016
Language:EN
The application published by WIPO in one of the EPO official languages on 18.09.2014 takes the place of the publication of the European patent application.
[2016/03]
Type: B1 Patent specification 
No.:EP2968297
Date:26.09.2018
Language:EN
[2018/39]
Search report(s)International search report - published on:KR18.09.2014
(Supplementary) European search report - dispatched on:EP27.10.2016
ClassificationIPC:A61K31/4439, A61K31/4427, A61K31/4178, A61P27/02
[2016/03]
CPC:
A61K31/4439 (EP,RU,US); A61K31/415 (EP,US); A61K31/444 (EP,US);
A61K31/4545 (EP,US); A61K31/506 (EP,US); A61K31/5377 (EP,US);
A61K45/06 (US); A61K9/0048 (US); A61P27/02 (EP,US);
A61P43/00 (RU); C07D231/38 (EP,US); C07D401/04 (EP,US);
C07D403/04 (EP,US); C07D405/14 (EP,US); C07D409/14 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/03]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:MULTISUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS SERINPROTEASEINHIBITOREN[2016/03]
English:MULTISUBSTITUTED AROMATIC COMPOUNDS AS SERINE PROTEASE INHIBITORS[2016/03]
French:COMPOSÉS AROMATIQUES MULTISUBSTITUÉS EN TANT QU'INHIBITEURS DE SÉRINE PROTÉASE[2016/03]
Entry into regional phase28.09.2015National basic fee paid 
28.09.2015Search fee paid 
28.09.2015Designation fee(s) paid 
28.09.2015Examination fee paid 
Examination procedure28.09.2015Examination requested  [2016/03]
24.05.2017Amendment by applicant (claims and/or description)
19.10.2017Despatch of a communication from the examining division (Time limit: M04)
20.02.2018Reply to a communication from the examining division
19.04.2018Communication of intention to grant the patent
17.08.2018Fee for grant paid
17.08.2018Fee for publishing/printing paid
17.08.2018Receipt of the translation of the claim(s)
Divisional application(s)EP18189634.1  / EP3421036
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  19.10.2017
Opposition(s)27.06.2019No opposition filed within time limit [2019/36]
Request for further processing for:15.08.2016Request for further processing filed
15.08.2016Full payment received (date of receipt of payment)
Request granted
23.09.2016Decision despatched
Fees paidRenewal fee
08.03.2016Renewal fee patent year 03
07.03.2017Renewal fee patent year 04
27.03.2018Renewal fee patent year 05
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAL26.09.2018
CY26.09.2018
LV26.09.2018
MK26.09.2018
RS26.09.2018
SM26.09.2018
MT17.03.2019
[2022/31]
Former [2021/26]AL26.09.2018
CY26.09.2018
LV26.09.2018
RS26.09.2018
SM26.09.2018
MT17.03.2019
Former [2020/29]AL26.09.2018
LV26.09.2018
RS26.09.2018
SM26.09.2018
MT17.03.2019
Former [2019/27]AL26.09.2018
LV26.09.2018
RS26.09.2018
SM26.09.2018
Former [2019/13]AL26.09.2018
LV26.09.2018
RS26.09.2018
Former [2019/11]RS26.09.2018
Documents cited:Search[A]WO2008016883  (ACTIVESITE PHARMACEUTICALS INC [US], et al) [A] 1-23* See the compounds defined in the claims and in tqable 1, as kallikrenin inhibitors *;
 [I]WO2011126903  (VERSEON INC [US], et al) [I] 1-23 * See the compounds defined by the Markush formula IIIb in claims 1, 2, 17 and the specific compounds 37-45 disclosed in the examples, for use as thrombin inhibitors and for the treatment of thrombosis, fibrosis, cancer, pain and and other relevant disorders *;
 [A]  - YIFENG XIONG ET AL, "Discovery and Structure-Activity Relationship of 3-Methoxy- N -(3-(1-methyl-1 H -pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide (APD791): A Highly Selective 5-Hydroxytryptamine 2A Receptor Inverse Agonist for the Treatment of Arterial Thrombosis", JOURNAL OF MEDICINAL CHEMISTRY, US, (20100610), vol. 53, no. 11, doi:10.1021/jm100044a, ISSN 0022-2623, pages 4412 - 4421, XP055290414 [A] 1-23 * See the disclosed compounds as useful agents for treating trombosis and other associated conditions *

DOI:   http://dx.doi.org/10.1021/jm100044a
International search[A]US2002055639  (NEBEL KURT [CH], et al);
 [A]WO2004035564  (SYNGENTA PARTICIPATIONS AG [CH], et al);
 [A]US2008188527  (CASHMAN JOHN R [US]);
 [A]WO2012065019  (EXELIXIS INC [US], et al);
 [A]US2013040950  (SHORT KEVIN MICHAEL [US], et al)
by applicantUS4861760
 US4911920
 US5212162
 US5403841
 WO9605309
 US7625944
 WO2011126903
 US2012264798
 US2013040950
    - KEEL, M.; TRENTZ, O., Injury, (20050000), vol. 36, pages 691 - 709
    - BIRD et al., Thrombosis and Hemostasis, (20120000), vol. 107, page 1141
    - FEENER, E. P., Curr Diab Rep, (20100000), vol. 10, page 270
    - BADER M., Arteriosclerosis, Thrombosis, and Vascular Biology, (20090000), vol. 29, page 617
    - MIURA S., Hypertension, (20030000), vol. 41, page 1118
    - SYED, B.A.; EVANS, J.B.; BIELORY, L., Nature Reviews Drug Discovery, (20120000), vol. 11, page 827
    - TELANDER, D., Seminars in Ophthalmology, (20110000), vol. 26, no. 3, page 192
    - DUCHENE, "Kallikrein-kinin kystem in inflammatory diseases", Kinins. De Gruyter, (20110000), page 261
    - SCHNEIDER L et al., J Allergy Clin Immunol, (20070000), vol. 120, page 416
    - CALIENDO et al., J. Med. Chem., (20120000), vol. 55, page 6669
    - FREITAS et al., Bioorganic & Medicinal Chemistry Letters, (20120000), vol. 22, pages 6072 - 6075
    - RENNE, T.; GRUBER, A., Thromb Haemost, (20120000), vol. 107, pages 1012 - 3
    - SOTIROPOULOU, G.; PAMPALAKIS, G., Trends in Pharmacological Sciences, (20120000), vol. 33, pages 623 - 634
    - "Pharmacological Targeting of Human Tissue Kallikrein-Related Peptidases", PAMPALAKIS, G.; SOTIROPOULOU, G., Proteinases as Drug Targets, The Royal Society of Chemistry, (20120000), pages 199 - 228
    - CALIENDO, G.; SANTAGADA, V.; PERISSUTTI, E.; SEVERINO, B.; FIORINO, F.; FRECENTESE, F.; JULIANO, L., J Med Chem, (20120000), vol. 55, pages 6669 - 86
    - WIELAND, H. A. et al., Curr Opin Investig Drugs, (20030000), vol. 4, pages 264 - 71
    - GROSS, P. L.; WEITZ, J. I., Arterioscler Thromb Vasc Biol, (20080000), vol. 28, pages 380 - 6
    - HIRSH, J. et al., Blood, (20050000), vol. 105, pages 453 - 63
    - PREZELJ, A. et al., Curr Pharm Des, (20070000), vol. 13, pages 287 - 312
    - GODING, MONOCLONAL ANTIBODIES PRINCIPLES AND PRACTICE, Academic Press, (19860000), page 104
    - "Pro-drugs as Novel Delivery Systems", T. HIGUCHI; V. STELLA, A.C.S. Symposium Series, American Chemical Society, (19750000), vol. 14
    - B CARRIERS IN DRUG DESIGN: THEORY AND APPLICATION, Pergamon Press, (19870000), pages 14 - 21
    - MOREAU, M.E., Journal of Pharmacological Sciences, (20050000), vol. 99, page 6
    - ZACHARSKI, L. R.; LEE, A. Y., Expert Opin Investig Drugs, (20080000), vol. 17, pages 1029 - 1037
    - FALANGA, A.; PICCIOLI, A., Current Opinion in Pulmonary Medicine, (20050000), vol. 11, pages 403 - 407
    - SMORENBURG, S. M. et al., Thromb Haemost, (19990000), vol. 82, pages 1600 - 1604
    - HETTIARACHCHI, R. J. et al., Thromb Haemost, (19990000), vol. 82, pages 947 - 952
    - LEE, A. Y. et al., J Clin Oncol, (20050000), vol. 23, pages 2123 - 2129
    - KLERK, C. P. et al., J Clin Oncol, (20050000), vol. 23, pages 2130 - 2135
    - KAKKAR, A. K. et al., J Clin Oncol, (20040000), vol. 22, pages 1944 - 1948
    - ALTINBAS, M. et al., J Thromb Haemost, (20040000), vol. 2, pages 1266 - 1271
    - AKL, E. A. et al., JExp Clin Cancer Res, (20080000), vol. 27, page 4
    - HUA, Y. et al., Acta Neurochir, (20050000), vol. 2005, no. 95, pages 403 - 406
    - HUA, Y. et al., J Thromb Haemost, (20050000), vol. 3, pages 1917 - 1923
    - HUGHES, B., Nat Rev Drug Discov, (20100000), vol. 9, pages 903 - 906
    - DEFEO, K. et al., Thrombosis Research, (20100000), vol. 125, no. 2, pages S188 - S188
    - DEFEO, K. et al., Cancer Biol Ther, (20100000), vol. 10, pages 1001 - 1008
    - HU, L. et al., Blood, (20040000), vol. 104, pages 2746 - 51
    - NIEMAN, M. T. et al., J Thromb Haemost, (20080000), vol. 6, pages 837 - 845
    - NIEMAN, M. T. et al., Thromb Haemost, vol. 104, pages 1044 - 8
    - VAN NOORDEN, C. J. et al., Thromb Res, (20100000), vol. 125, no. 2, pages S77 - 79
    - DUPLANTIER, J. G. et al., Gut, (20040000), vol. 53, pages 1682 - 1687
    - ABDEL-SALAM, O. M. et al., Pharmacol Res, (20050000), vol. 51, pages 59 - 67
    - ASSY, N. et al., Dig Dis Sci, (20070000), vol. 52, pages 1187 - 1193
    - ABE, W. et al., J Hepatol, (20070000), vol. 46, pages 286 - 294
    - FAVREAU, F. et al., Am J Transplant, (20100000), vol. 10, pages 30 - 39
    - SILVER, R. M. et al., Am. J. Respir. Crit. Care Med., (20100000), vol. 181, page A6780
    - BOGATKEVICH, G. S. et al., Arthritis Rheum, (20090000), vol. 60, pages 3455 - 3464
    - CALVARUSO, V. et al., Gut, (20080000), vol. 57, pages 1722 - 1727
    - CHAMBERS, R. C., Br J Pharmacol, (20080000), vol. 153, no. 1, pages S367 - 378
    - CHAMBERS, R. C.; LAURENT, G. J., Biochem Soc Trans, (20020000), vol. 30, pages 194 - 200
    - HOWELL, D. C. et al., Am J Pathol, (20010000), vol. 159, pages 1383 - 1395
    - CLEMENTS, J.A., The Molecular Biology of the Kallikreins and Their Roles in Inflammation, Academic Press, (19970000), vol. 5
    - COLMAN, R.W., Clinical Reviews in Allergy and Immunology, (19980000), vol. 16, page 365
    - LOPEZ, P.F., Investigative Ophthalmology & Visual Science, (19960000), vol. 37, page 855
    - FERRARA, N., Current Opinion in Biotechnology, (20000000), vol. 11, page 617
    - VAUGHAN, P. J. et al., Brain Res, (19940000), vol. 668, pages 160 - 170
    - YIN, X. et al., Am J Pathol, (20100000), vol. 176, pages 1600 - 1606
    - AKIYAMA, H. et al., Neurosci Lett, (19920000), vol. 146, pages 152 - 154
    - HAN, M. H. et al., Nature, (20080000), vol. 451, pages 1076 - 1081
    - CHELMICKA-SZORC, E.; ARNASON, B. G., Arch Neurol, (19720000), vol. 27, pages 153 - 158
    - INABA, Y. et al., Cell Immunol, (19990000), vol. 198, pages 96 - 102
    - WIEDERMANN, C. J.; ROMISCH, J., Acta Med Austriaca, (20020000), vol. 29, pages 89 - 92
    - LUO, W. et al., THROMBIN, Springer, (20090000), pages 133 - 159
    - GARCIA, P. S. et al., Thromb Haemost, (20100000), vol. 103, pages 1145 - 1151
    - NARITA, M. et al., JNeurosci, (20050000), vol. 25, pages 10000 - 10009
    - BERGE et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science, (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - PHARMACEUTICAL SCIENCES, Mack Pub. Co.
    - Remington's Pharmaceutical Sciences, Mack Publishing Co., (19750000), pages 1405 - 1412,1461-1487
    - LANGER, Science, (19900000), vol. 249, page 1527
    - MILLER-KEANE, ENCYCLOPEDIA & DICTIONARY OF MEDICINE, NURSING & ALLIED HEALTH, W. B. Saunders Co., (19920000), page 1708,1651
    - FINGL et al., THE PHARMACOLOGICAL BASIS OF THERAPEUTICS, (19750000), page l
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.